A double-blind clinical study comparing tolerability, safety, and efficacy of Hexabrix and Renografin-76 for intravenous subtraction angiography.
In a double-blind study of neurologic patients, the safety and efficacy of Hexabrix was compared with Renografin-76 in intravenous digital subtraction angiography. There was no difference in quality of the 26 Hexabrix and 24 Renografin exams using the continuous recursive filtration system. Subjective patient discomfort was less with Hexabrix. There was no significant difference in tolerability and safety between the two agents.
D000703:Analog-Digital Conversion; D000792:Angiography / Q000009:adverse effects / Q000379:methods*; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D003973:Diatrizoate / Q000009:adverse effects / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine / Q000009:adverse effects; D004311:Double-Blind Method; D004338:Drug Combinations / Q000009:adverse effects; D006801:Humans; D007463:Iodobenzoates; D007485:Ioxaglic Acid; D013382:Subtraction Technique; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D004338:Drug Combinations; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision; D007485:Ioxaglic Acid